EWTX
Edgewise Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$39.63-0.33%
Price as of Jul 20, 2026
EWTX ownership
Edgewise Therapeutics, Inc. ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
4
Net (3m)
-$10.0M
Insider trades by month Buys Sells
Nov
Jan
Mar
Apr
May
Jul
Context3-month price +47.3%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Sell | 69,648 | $39.41 |
| Jul 2, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Option | 69,648 | $0.18 |
| Jul 2, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Sell | 130,352 | $39.41 |
| Jul 2, 2026 | Russell Alan Jdirector, officer: Chief Scientific Officer | Option | 130,352 | $0.45 |
| Jul 1, 2026 | Fox Jonathan Cdirector | Grant | 319 | — |
| Jun 17, 2026 | Brege Lauradirector | Grant | 16,377 | $35.59 |
| Jun 17, 2026 | Thompson Peter A.director, 10 percent owner: | Grant | 16,377 | $35.59 |
| Jun 17, 2026 | Morris Arlenedirector | Grant | 16,377 | $35.59 |
| Jun 16, 2026 | Edris Badreddindirector | Grant | 8,188 | $35.59 |
| Jun 16, 2026 | Martin Christopher Nathandirector | Grant | 16,377 | $35.59 |
| Jun 16, 2026 | Fox Jonathan Cdirector | Grant | 16,377 | $35.59 |
| Jun 16, 2026 | Edris Badreddindirector | Grant | 5,619 | — |
| May 5, 2026 | Donovan Joanne M.officer: CMO | Sell | 5,230 | $31.29 |
| May 5, 2026 | Donovan Joanne M.officer: CMO | Sell | 50,000 | $38.57 |
| May 5, 2026 | Donovan Joanne M.officer: CMO | Option | 50,000 | $7.08 |
| Apr 3, 2026 | Fox Jonathan Cdirector | Grant | 339 | — |
| Apr 2, 2026 | Donovan Joanne M.officer: CMO | Sell | 28,662 | $32.31 |
| Apr 2, 2026 | Donovan Joanne M.officer: CMO | Option | 28,662 | $7.08 |
| Mar 31, 2026 | Donovan Joanne M.officer: CMO | Sell | 21,338 | $32.12 |
| Mar 31, 2026 | Donovan Joanne M.officer: CMO | Option | 21,338 | $7.08 |
| Mar 30, 2026 | Donovan Joanne M.officer: CMO | Sell | 9,623 | $30.98 |
| Mar 30, 2026 | Donovan Joanne M.officer: CMO | Sell | 6,735 | $30.98 |
| Jan 23, 2026 | Edris Badreddindirector | Sell | 13,690 | $29.44 |
| Jan 23, 2026 | Edris Badreddindirector | Option | 66,477 | $1.93 |
| Jan 23, 2026 | Edris Badreddindirector | Option | 7,605 | $0.71 |
| Jan 23, 2026 | Edris Badreddindirector | Option | 17,236 | $0.64 |
| Jan 23, 2026 | Edris Badreddindirector | Option | 13,690 | $0.39 |
| Jan 23, 2026 | Edris Badreddindirector | Sell | 66,477 | $29.44 |
| Jan 23, 2026 | Edris Badreddindirector | Option | 10,463 | $1.93 |
| Jan 23, 2026 | Edris Badreddindirector | Sell | 10,463 | $29.44 |
Source: EWTX SEC Form 4 filings, latest Jul 2, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their EWTX positions over the last 6 months (SEC Form 13F).
Increased
140
New positions
88
Reduced
129
Sold out
49
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| ORBIMED ADVISORS LLC | Unchanged | 15.5M | Feb 17, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 15.5M | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 10.4M | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 10.4M | Feb 17, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Increased | 7.4M | May 15, 2026 |
| BLACKROCK, INC. | Increased | 6.6M | Feb 12, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 6.6M | May 15, 2026 |
| BAKER BROS. ADVISORS LP | Reduced | 6.6M | Feb 17, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Increased | 6.5M | Feb 17, 2026 |
| BLACKROCK, INC. | Reduced | 6.5M | May 13, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 5.9M | May 18, 2026 |
| NOVO HOLDINGS A/S | Unchanged | 5.3M | Feb 17, 2026 |
| NOVO HOLDINGS A/S | Unchanged | 5.3M | May 15, 2026 |
| BRAIDWELL LP | Unchanged | 5.2M | Feb 17, 2026 |
| VANGUARD GROUP INC | Increased | 4.9M | Jan 29, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.